Navigation Links
Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV).

The asset, designated RPC4046 by Receptos, has completed a first-in-human Phase I study. Under the agreement, Receptos will conduct a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the US FDA. AbbVie holds an exclusive option to enter into a global co-development collaboration for RPC4046 with Receptos following results of the planned Phase 2 study and regulatory discussions with the FDA.

"We are honored that AbbVie has entrusted a promising Phase 2-ready therapeutic candidate to the Receptos development team to pursue proof-of-concept in EoE, an Orphan Disease growing in prevalence for which there are no approved treatment options," said Faheem Hasnain , President and Chief Executive Officer of Receptos. "We believe that AbbVie's exceptional track record in immunology will be a strong asset in this collaboration."

Upon exercise of the co-development option, AbbVie and Receptos would enter into a collaboration agreement in which the parties would equally share costs of the Phase 3 clinical program and future development on a global basis. Receptos would retain a right to co-promote RPC4046 and share equally in profits in the United States. Outside of the US, AbbVie would hold sole commercial rights and Receptos would be eligible for double digit royalties on net sales. Additional indications may be pursued under the collaboration, as the mechanism of action has been shown to have potential in various immunological and allergic disorders.

Should AbbVie decline to exercise its co-development option for RPC4046, Receptos would obtain a
'/>"/>

SOURCE Receptos Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
2. Graham Cooper Appointed Chief Financial Officer of Receptos
3. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
4. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
5. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
6. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
7. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
8. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
9. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
10. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
11. NTT DATA Licenses DATATRAK ONE™ for China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... In response to urgent requests from the Deputy Minister ... Leone , Direct Relief delivered two 10-bed medical tents ... of local health workers who contract Ebola while fighting the ... center was constructed for foreign health care workers who may ... local Sierra Leonean health workers. With ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Pfizer Inc. (NYSE: PFE ) have launched ... therapies for Duchenne muscular dystrophy (DMD). At the heart ... exchange of expertise that brings the respective strengths of ... hold promise for benefitting DMD patients in the future. ...
... ANN ARBOR, Mich., Nov. 9, 2011 ... company developing and commercializing innovative diagnostics and ... CardioDefender diagnostic system.  CardioDefender is the first ... to provide physicians and patients with hospital-quality ...
Cached Medicine Technology:Children's Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics 2Children's Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics 3Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 2Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 3Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 4Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 5
(Date:12/26/2014)... 26, 2014 India Network Foundation, a ... the USA, announced today a new version of “ ... choosing the right plan for their visiting parents. The ... of the selection process when choosing an insurance plan ... with only a few clicks. Many elderly Asian Indian ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... in Australia have developed a process for rapidly and efficiently ... parts, potentially allowing doctors //to do blood tests without sending ... the same principle that causes tea leaves to accumulate at ... phenomenon first explained by Einstein in the 1920s. ...
... a frozen embryo at the time of the hurricane Katrina floods, ... ,The baby has been named Noah, after the great survivor. Noah ... frozen in liquid nitrogen when floods hit the hospital. ... third as the hurricane waters entered the hospital and rose till ...
... have created a new method for fighting Leukemia. ... of a novel agent that triggers programmed cell death, ... for fighting leukemia and other malignancies. ,The ... cancer cells. The process is regulated by a large ...
... has demonstrated China’s renewed commitment to check animal diseases. China ... dollars) to control and prevent animal diseases. // ,The ... bird flu, foot-and-mouth disease, by 2015 and possibly even root ... will enable about 5.66 billion yuan and the remaining amount ...
... designed a vitamin D tablet Asentar, to treat advanced prostate ... slow down certain cancers. But consuming natural levels// of the ... levels of vitamin D 50-100 times higher than normal and ... prostate cancer along with chemotherapy drugs. ,Asentar is ...
... death in the U.S.; more than 30,000 Americans are expected ... cancer is an extremely difficult cancer to treat and little ... in pancreatic cancer is cigarette smoking; other links have been ... a new study, researchers at the Harvard School of Public ...
Cached Medicine News:Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2Health News:New Method For Fighting Leukemia 2Health News:Vitamin D Tablets to Cure Prostate Cancer 2Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2
... percutaneously to direct a .038 ... guide to a specific renal ... an inner stainless steel braid ... the catheter shaft. Supplied sterile ...
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages. ...
Medicine Products: